As a functional genomics company, Lexicon Genetics Inc. has busied itself churning out validated targets using its knockout mouse technology. But without additional components of a drug discovery engine, LEXG was faced with the choice of either out-licensing its targets or warehousing them. With last week's proposed $32 million stock acquisition of Coelacanth Corp., LEXG gains